MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • Heatmap
  • Русский
  • 中文
  • Español
  • Português
  • 日本語
  • Deutsch
  • 한국어
  • Français
  • Italiano
  • Türkçe
Keros Therapeutics, Inc. Common Stock

KROS

#3576
Keros Therapeutics, Inc. Common Stock
11.3800 USD
+2.06%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
11.3800
11.4300
Year Range
10.4150
22.5500
Daily Change
+2.06%
Monthly Change
+2.99%
6 month change
-24.64%
Year Change
-24.64%
Previous Close
11.1500
Open
11.4101
Bid
Ask
Low
11.3800
High
11.4300
Volume
33
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. KROS
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 224.3855 M
  • Employee 78
  • Founded 2015
  • CEO N/A
  • Website www.kerostx.com
  • Headquarter Massachusetts, United States
  • FIGI BBG00H1HP9G9
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
224.39 M Market capitalization
Price to earnings ratio
8.85
Price to sales ratio
3.16

News

Zacks Zacks
INSM KROS
2026.03.31
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
Zacks Zacks
SRPT PTCT KROS
2026.03.17
KROS: Is the Discount Book Value a Value Trap?
Zacks Zacks
SRPT PTCT KROS
2026.03.17
KROS Stock: What to Know About Rinvatercept in DMD
Zacks Zacks
SRPT PTCT KROS
2026.03.17
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Zacks Zacks
SRPT PTCT KROS
2026.03.06
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Zacks Zacks
BMY GERN KROS
2026.03.05
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
Zacks Zacks
KROS
2026.03.04
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Investing Investing
KROS
2026.03.04
Keros earnings missed by $0.16, revenue fell short of estimates
Zacks Zacks
SRPT TAK KROS
2026.02.18
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
Zacks Zacks
BMY JNJ KROS
2026.02.03
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
Zacks Zacks
ALKS SRPT CSTL KROS
2026.01.27
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
Zacks Zacks
DYN KROS
2026.01.27
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Market
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
Scan to install from App Store
Scan to install from Google Play
Scan to install from Huawei AppGallery
Scan to install APK
MQL5 Channels
Scan to install from App Store
Scan to install from Google Play
Scan to install from Huawei AppGallery
Scan to install APK
Economic Calendar
Scan to install from App Store
Scan to install from Google Play
Scan to install from Huawei AppGallery
Scan to install APK
Risk Disclosure Terms of Use Help Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd